Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

Importance: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed. Objective: To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer. Design, Setting, and Participants: Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy. Interventions: Eligible patients were randomized 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m2 twice a day by mouth for 1 year without interruption or to observation (n = 221) after completion of standard adjuvant chemotherapy. Main Outcomes and Measures: The primary end point was disease-free survival. Secondary end points included distant disease-free survival, overall survival, locoregional recurrence-free survival, and adverse events. Results: Among 443 women who were randomized, 434 were included in the full analysis set (mean [SD] age, 46 [9.9] years; T1/T2 stage, 93.1%; node-negative, 61.8%) (98.0% completed the trial). After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. The estimated 5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; P = .03). In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; P = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of death, 0.75 [95% CI, 0.47-1.19]; P = .22), and the estimated 5-year locoregional recurrence-free survival was 85.0% vs 80.8% (HR for risk of locoregional recurrence or death, 0.72 [95% CI, 0.46-1.13]; P = .15). The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with 7.7% of patients experiencing a grade 3 event. Conclusions and Relevance: Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival. Trial Registration: ClinicalTrials.gov Identifier: NCT01112826.

Polysiloxane-based luminescent elastomers prepared by thiol-ene "click" chemistry.

Side-chain vinyl poly(dimethylsiloxane) has been modified with mercaptopropionic acid, methyl 3-mercaptopropionate, and mercaptosuccinic acid. Coordinative bonding of Eu(III) to the functionalized polysiloxanes was then carried out and crosslinked silicone elastomers were prepared by thiol-ene curing reactions of these composites. All these europium complexes could be cast to form transparent, uniform, thin elastomers with good flexibility and thermal stability. The networks were characterized by FTIR, NMR, UV/Vis, and luminescence spectroscopy as well as by scanning electron microscopy, thermogravimetric analysis, and X-ray photoelectron spectroscopy. The europium elastomer luminophores exhibited intense red light at 617 nm under UV excitation at room temperature due to the (5)D0 →(7)F2 transition in Eu(III) ions. The newly synthesized luminescent materials offer many advantages, including the desired mechanical flexibility. They cannot be dissolved or fused, and so they have potential for use in optical and electronic applications.

Improvement of silicone rubber properties by addition of nano-SiO2 particles.

AIMS: To improve the comprehensive performances of a one-part room temperature vulcanized silicone rubber(RTV-1 SiR), Nano-SiO2 particles are employed as the reinforcing agent. MATERIALS AND METHODS: The SiO2/RTV-1 SiR composite is prepared using PDMS, ND42, D-60 and HMDS-modified SiO2 particles by mixing method. And then, the mechanical and electrical properties, including shear strength, tensile strength, hardness Shore A and volume resistivity, are investigated using experimental method. RESULTS: The addition of nano-SiO2 particles can improve the properties of the SiO2/RTV-1 SiR composite in different degrees. And, the incorporation of 25~30 phr nano-SiO2 particles is found to be reasonable for silicone rubber composite with the best comprehensive performances. CONCLUSIONS: The significant improvement of mechanical properties and electrical insulation of SiO2 may be contributed to the addition of modified nano-SiO2 particles. Additionally, the excellent comprehensive performances of SiO2/RTV-1 SiR composite guarantee a potential applications as electrical-insulating adhesives.